Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma-Reference-Cited by-同舟云学术

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma

Published:2022-02-15 Issue:3 Volume:6 Page:e691
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Puertas Borja,Mateos María-Victoria,González-Calle Verónica

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference15 articles.

1. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.;Gandhi;Leukemia,2019

2. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.;Mateos;J Clin Oncol,2021

3. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.;Mateos;HemaSphere,2021

4. Multiple myeloma: patient outcomes in real-world practice.;Yong;Br J Haematol,2016

5. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.;Raje;N Engl J Med,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on CAR T cell therapy in multiple myeloma;Biomarker Research;2024-09-12

2. CARs moving forward: The development of CAR T-cell therapy in the earlier treatment course of hematologic malignancies;Seminars in Hematology;2024-08

3. miR‐34a promotes the immunosuppressive function of multiple myeloma‐associated macrophages by dampening the TLR‐9 signaling;Cancer Medicine;2024-06

4. CAR T therapies in multiple myeloma: unleashing the future;Cancer Gene Therapy;2024-03-04

5. Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight;Leukemia Research Reports;2024